Salvat Laboratories announces submission of New Drug Application to the U.S. FDA for Clobetasol Nanoemulsion for treating inflammation and pain after ocular surgery
- Details
- Category: Business

This submission comes after two successful phase III clinical trials conducted between 2020 and 2021.
Pfizer and BioNTech announce positive early data from clinical trial of Omicron BA.4/BA.5-adapted bivalent booster in individuals 18 years and older
- Details
- Category: Pfizer

Bayer signs grant agreement to advance innovation in non-hormonal contraception
- Details
- Category: Bayer

GSK announces expanded collaboration with Tempus in precision medicine to accelerate R&D
- Details
- Category: GlaxoSmithKline

Pfizer completes acquisition of Global Blood Therapeutics
- Details
- Category: Pfizer

Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities
- Details
- Category: Eli Lilly and Company

Pfizer completes acquisition of Biohaven Pharmaceuticals
- Details
- Category: Pfizer

More Pharma News ...
- Evusheld long-acting antibody combination approved in the EU for the treatment of COVID-19
- Pfizer to supply Global Fund up to 6 million PAXLOVID™ treatment courses for low-and-middle-income countries
- WHO grants prequalification to GSK's Mosquirix - the first and only approved malaria vaccine
- Pfizer and BioNTech receive positive CHMP opinion for Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster in European Union
- Novartis invests in early technical development capabilities for next-generation biotherapeutics
- FDA grants Breakthrough Therapy Designation to Pfizer's Group B Streptococcus vaccine candidate
- Xenpozyme™ (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations)